Lenograstim

Drug #1173

Lenograstim is a recombinant human granulocyte-colony stimulating factor (rhG-CSF) that stimulates the production of neutrophils and may reduce the duration of chemotherapy-induced neutropeniaand there by reduce the incidence of associated sepsis; there is yet no evidence thet it improvesoverall survival. I

← Previous drug Next drug →

Primary Characteristics

It is of Semi Synthetic origin and belongs to .

It belongs to Granulocyte colony stimulating factor agonist pharmacological group on the basis of mechanism of action. It is also classified under Hematological Agents .

Solubility in Water: null · Solubility in Alcohol: null · Non-proprietary name: Lenograstin.

Pharmacokinetics

Distribution: Lenograstim has a volume of distribution is . plasma protein binding is .

Elimination: it is metabolised via , plasma half-life is , renal excretion is .

Indications

Lenograstim is primarily indicated in conditions like Bone marrow transplantation, Cytotoxic-induced neutropenia, Mobilisation of peripheral blood progenitor cells, Neutropenia, Reduction in the duration of neutropenia following bone marrow transplantation.

Contraindications

Lenograstim is contraindicated in conditions like Kostmans syndrome.

Dosage

Lenograstim's dosage details are as follows:

Dose	Single Dose	Frequency	Route	Instructions
Adult Dosage
150 ug/m2eter	150 ug/m2eter	Every 24h	SC,IV Inf	Started the day after transplantation /chemotherapy completion.
Paediatric Dosage (20kg)
19.2 million unit/sq metre	19.2 million unit/sq metre	Every 24h	IV Infusion	Not use more than 28 days .Dose recommended for paeds over 2 Yrs
19.2 million/sq metre	19.2 million/sq metre	Every 24h	Subcutaneous	Not use more than 28 days .Dose recommended for paeds over 2 Yrs .
Neonatal Dosage (3kg)
No data.

Drug Interactions

None recorded.

Side Effects

Lenograstim in overdosage may give rise to further complications which include Anemia , Anemia , Thrombocytopenia , Disturbed hepatic function , Disturbed hepatic function , Anemia, Anemia.

Lenograstim is known to cause more or less tolerable side effects which are usually transient. These include Bone pain, Diarrhea, Epistaxis, Headache, Hypotension , Musculoskeletal pain , Proteinuria , Uricemia, Vasculitis.

Warnings / Precautions

Caution should be taken if tumours with myeloid characteristics (risk of the tumour growth), pre-malignant myeloid conditions is present. Reduced myeloid precursors, monitor leucocyte count (discontinue treatment if leucocylossis); monitor platelet count and hemoglobin; regular morphological and cytogenetic bone marrow examinations recommended in severe congenital neutropenia (possible risk of myelodysplastic syndromes or leukemia) monitor spleen size, osteoporotic bone disease ( monitor bone marrow densityif given for more than 6 months).

Available Brands

Click on a strength to view available brands.

Single Ingredient

Inj

33.6 MIU

Storage Conditions

Lenograstim should be stored Inj, Inf.

Drug Classification

1.10.4 — Anabolics & hematopoietics

Manufacturers

Manufacturers of Lenograstim in Pakistan:

Aventis